Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells.
Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.
MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.
Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.
Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads.
Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
Human dendritic cells sequentially matured with CD4(+) T cells as a secondary signal favor CTL and long-term T memory cell responses.
Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth.
Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus.
Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells.
A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy.
Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity.
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells.
Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.
Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells.
A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
Dendritic cell preparation for immunotherapeutic interventions.
Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy.
A Spliced Antigenic Peptide Comprising a Single Spliced Amino Acid Is Produced in the Proteasome by Reverse Splicing of a Longer Peptide Fragment followed by Trimming.